

31 May 2017

## TENDER RESULTS

PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2016/17 Invitation to Tender, dated 3 November 2016.

Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply/Hospital Supply Status commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.

### **Notification of Product Changes (NOPC) forms, Containered Trade Product Pack (CTPP) codes and Pharmacodes**

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to notify any changes to PHARMAC and the Pharmacy Guild of New Zealand by 4pm on the **12<sup>th</sup> of the month prior to the date of subsidy change**. More information and NOPC forms can be found on our website – <http://www.pharmac.health.nz/medicines/how-medicines-are-funded/new-funding-applications/pharmaceutical-product-specifications-the-change-process>

Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand (<http://www.pgnz.org.nz/pharmacode>) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines (<http://www.nzulm.org.nz/sponsors>). Pharmacodes and CTPP codes must be provided to PHARMAC by the 5<sup>th</sup> of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest). PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.

**2016/17 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2020**

**Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule**

1. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current subsidy (and price)	New subsidy (and price)	Sole supply brand (Supplier)	Date of subsidy change	Sole Subsidised Supply date
Brimonidine tartrate*	Eye drops 0.2%; 5 ml OP bottle	\$4.32	\$4.29	Arrow-Brimonidine (Actavis)	1 December 2017	1 March 2018
Neostigmine metisulfate	Inj 2.5 mg per ml, 1 ml; 50 ampoules	\$98.00	\$98.00	AstraZeneca (AstraZeneca)	1 September 2017	1 December 2017
Rifaximin	Tab 550 mg; 56 tablets; blister pack	\$625.00	\$625.00	Xifaxan (Norgine)	1 July 2017	1 October 2017

\*This product will be supplied at the Price from the 1<sup>st</sup> day of the month prior to the listing date, as per Schedule 5, clause 3.1 (b)(II) of the 2016/17 Invitation To Tender.

2. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current subsidy (and price)	New subsidy (and price)	Sole supply brand (Supplier)	Date of listing/subsidy change for tender winning brand	Date of reference pricing of other listed brands	Sole Subsidised Supply date (and delisting of other listed brands)	Brand (Supplier) affected by reference pricing and delisting
Anastrozole*	Tab 1 mg; 30 tablets; blister pack	\$26.55	\$5.04	Rolin (Rex Medical)	1 November 2017	1 January 2018	1 April 2018	Aremed (AFT) Arimidex (AstraZeneca) DP-Anastrozole (Douglas)
Bisoprolol fumarate**	Tab 2.5 mg; 90 tablets; blister pack	\$2.40 per 30 tablets	\$3.53	Bosvate (Douglas)	1 July 2017	1 September 2017	1 December 2017	Bosvate (Douglas) 30 tablet pack

Chemical name	Presentation; Pack size and type	Current subsidy (and price)	New subsidy (and price)	Sole supply brand (Supplier)	Date of listing/subsidy change for tender winning brand	Date of reference pricing of other listed brands	Sole Subsidised Supply date (and delisting of other listed brands)	Brand (Supplier) affected by reference pricing and delisting
Bisoprolol fumarate**	Tab 5 mg; 90 tablets; blister pack	\$3.50 per 30 tablets	\$5.15	Bosvate (Douglas)	1 July 2017	1 September 2017	1 December 2017	Bosvate (Douglas) 30 tablet pack
Bisoprolol fumarate**	Tab 10 mg; 90 tablets; blister pack	\$6.40 per 30 tablets	\$9.40	Bosvate (Douglas)	1 July 2017	1 September 2017	1 December 2017	Bosvate (Douglas) 30 tablet pack
Ethinylestradiol with levonorgestrel	Tab 20 mcg with levonorgestrel 100 mcg and 7 inert tablets; 84 tablets; blister pack	\$2.65	\$2.18	Microgynon 20 ED (Bayer)	1 November 2017	1 January 2018	1 April 2018	Ava 20 ED (Actavis)
Ethinylestradiol with levonorgestrel	Tab 30 mcg with levonorgestrel 150 mcg and 7 inert tablets; 84 tablets; blister pack	\$2.30	\$1.77	Levlen ED (Bayer)	1 November 2017	1 January 2018	1 April 2018	Ava 30 ED (Actavis)
Macrogol 3350 with potassium chloride, sodium bicarbonate and sodium chloride	Powder for oral soln 13.125 g with potassium chloride 46.6 mg, sodium bicarbonate 178.5 mg and sodium chloride 350.7 mg; 30 sachets	\$7.65	\$6.78	Molaxole (Mylan)	1 December 2017	1 February 2018	1 May 2018	Lax-Sachets (AFT)

\* Brand switch fee of \$4.50 is payable for this product from 1 April 2018 until 1 July 2018.

\*\*The three months dispensed all-at-once (Stat dispensing) rule will be added to bisoprolol fumarate tablets from 1 December 2017.

## Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

### 3. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current price	New price	Hospital Supply Brand (Supplier)	DV Limit	Listing date	Hospital Supply Status date
Brimonidine tartrate*	Eye drops 0.2%; 5 ml bottle	\$4.32	\$4.29	Arrow-Brimonidine (Actavis)	1%	1 December 2017	1 February 2018
Neostigmine metisulfate	Inj 2.5 mg per ml, 1 ml; 50 ampoules	\$98.00	\$98.00	AstraZeneca (AstraZeneca)	1%	1 September 2017	1 November 2017
Rifaximin	Tab 550 mg; 56 tablets; blister pack	\$625.00	\$625.00	Xifaxan (Norgine)	1%	1 July 2017	1 September 2017
Ropivacaine hydrochloride	Inj 2 mg per ml, 10 ml ampoule; 5 ampoules	\$9.05	\$8.80	Ropivacaine Kabi (Fresenius Kabi)	1%	1 July 2017	1 September 2017
Ropivacaine hydrochloride	Inj 2 mg per ml, 20 ml ampoule; 5 ampoules	\$9.50	\$9.20	Ropivacaine Kabi (Fresenius Kabi)	1%	1 July 2017	1 September 2017
Ropivacaine hydrochloride	Inj 7.5 mg per ml, 10 ml ampoule; 5 ampoules	\$10.20	\$9.90	Ropivacaine Kabi (Fresenius Kabi)	1%	1 July 2017	1 September 2017
Ropivacaine hydrochloride	Inj 7.5 mg per ml, 20 ml ampoule; 5 ampoules	\$12.50	\$12.15	Ropivacaine Kabi (Fresenius Kabi)	1%	1 July 2017	1 September 2017
Ropivacaine hydrochloride	Inj 10 mg per ml, 10 ml ampoule; 5 ampoules	\$10.90	\$10.55	Ropivacaine Kabi (Fresenius Kabi)	1%	1 July 2017	1 September 2017
Ropivacaine hydrochloride`	Inj 10 mg per ml, 20 ml ampoule; 5 ampoules	\$16.30	\$15.80	Ropivacaine Kabi (Fresenius Kabi)	1%	1 July 2017	1 September 2017
Suxamethonium chloride	Inj 50 mg per ml, 2 ml ampoule; 50 ampoules	\$78.00	\$78.00	AstraZeneca (AstraZeneca)	1%	1 September 2017	1 November 2017
Zinc and castor oil	Oint BP; 20 g tube	\$1.39	\$1.26	healthE (Jaychem)	1%	1 September 2017	1 November 2017

\*This product will be supplied at the Price from the 1<sup>st</sup> day of the month prior to the listing date, as per Schedules 6, clause 3.1 (b)(II) of the 2016/17 Invitation To Tender.

### 4. Tenders awarded to pharmaceuticals where at least one other brand is listed.

A1040241

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current price	New price	Hospital Supply Brand (Supplier)	DV Limit	Listing date	Hospital Supply Status date	Brand (Supplier) affected by delisting
Anastrozole	Tab 1 mg; 30 tablets; blister pack	\$26.55	\$5.04	Rolin (Rex Medical)	1%	1 November 2017	1 January 2018	Aremed (AFT) DP-Anastrozole (Douglas)
Bisoprolol fumarate	Tab 2.5 mg; 90 tablets; blister pack	\$2.40 per 30 tablets	\$3.53	Bosvate (Douglas)	1%	1 July 2017	1 September 2017	Bosvate (Douglas) 30 tablet pack
Bisoprolol fumarate	Tab 5 mg; 90 tablets; blister pack	\$3.50 per 30 tablets	\$5.15	Bosvate (Douglas)	1%	1 July 2017	1 September 2017	Bosvate (Douglas) 30 tablet pack
Bisoprolol fumarate	Tab 10 mg; 90 tablets; blister pack	\$6.40 per 30 tablets	\$9.40	Bosvate (Douglas)	1%	1 July 2017	1 September 2017	Bosvate (Douglas) 30 tablet pack
Ceftazidime	Inj 1 g vial; 1 vial	\$1.55	\$2.20	Hospira Ceftazidime (Pfizer)	1%	1 January 2018	1 March 2018	Fortum (GSK)
Cefuroxime	Inj 750 mg vial; 10 vials	\$3.70 per 5 vials	\$9.85	Cefuroxime Actavis (Actavis)	1%	1 December 2017	1 February 2018	Zinacef (GSK)
Cefuroxime	Inj 1.5 g vial; 10 vials	\$1.30 per vial	\$14.36	Cefuroxime Actavis (Actavis)	1%	1 December 2017	1 February 2018	Zinacef (GSK)
Ethinylestradiol with levonorgestrel	Tab 20 mcg with levonorgestrel 100 mcg and 7 inert tablets; 84 tablets; blister pack	\$2.65	\$2.18	Microgynon 20 ED (Bayer)	1%	1 November 2017	1 January 2018	Ava 20 ED (Actavis)
Ethinylestradiol with levonorgestrel	Tab 30 mcg with levonorgestrel 150 mcg and 7 inert tablets; 84 tablets; blister	\$2.30	\$1.77	Levlen ED (Bayer)	1%	1 November 2017	1 January 2018	Ava 30 ED (Actavis)

Chemical Name	Presentation; Pack size and type	Current price	New price	Hospital Supply Brand (Supplier)	DV Limit	Listing date	Hospital Supply Status date	Brand (Supplier) affected by delisting
	pack							
Macrogol 3350 with potassium chloride, sodium bicarbonate and sodium chloride	Powder for oral soln 13.125 g with potassium chloride 46.6 mg, sodium bicarbonate 178.5 mg and sodium chloride 350.7 mg; 28 sachets	\$7.65	\$6.78	Molaxole (Mylan)	1%	1 December 2017	1 February 2018	Lax-Sachets (AFT)

## Tender declines - Products where no tender is to be awarded for Sole Subsidised Supply Status or Hospital Supply Status

PHARMAC has resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in the 2015/16 Invitation to Tender, dated 6 November 2015 and the 2016/17 Invitation to Tender, dated 3 November 2016:

### 2015/16 Invitation to Tender

Chemical Name	Line Item	Chemical Name	Line Item
Condom lubricating jelly	<200 ml	Dorzolamide	Eye drops 2%
Condoms	Female condom		

### 2016/17 Invitation to Tender

Chemical Name	Line Item	Chemical Name	Line Item
Calcium carbonate	Tab eff 0.875 - 1.75 g (0.5 g - 1 g elemental)	Paclitaxel	Inj 600 mg
Cefuroxime	Oral suspension 25 mg per ml	Pivmecillinam	Tab 200 mg
Cefuroxime	Oral suspension 50 mg per ml	Prednisolone acetate	Eye drops 0.12%
Cidofovir	Inj 75 mg per ml, 5 ml	Pyrimethamine	Tab 25 mg
Ciprofloxacin with Hydrocortisone	Ear drops 0.2% with hydrocortisone 1%	Streptomycin sulphate	Inj 400 mg per ml, 2.5 ml
Coal tar	Shampoo 4% (pack size of 100 ml or less)	Testosterone	Transdermal patch 5 mg
Cyclopentolate hydrochloride	Eye drops 1%	Testosterone	Transdermal patch 2.5 mg
Fosfomycin	Powder for oral solution, 3 g sachet	Tobramycin	Eye drops 0.3%
Hydrocortisone Butyrate	Oint 0.1% (pack size of 100 g or less)	Tobramycin	Eye oint 0.3%
Ivermectin	Cream 1%	Trimethoprim	Tab 100 mg

Chemical Name	Line Item	Chemical Name	Line Item
Lithium carbonate	Cap 250 mg	Trimethoprim	Oral liq
Lopinavir with Ritonavir	Oral liq 80 mg with ritonavir 20 mg per ml	Trimethoprim with sulphamethoxazole [Co-trimoxazole]	Tab trimethoprim 80 mg and sulphamethoxazole 400 mg
Lopinavir with ritonavir	Tab 100 mg with ritonavir 25 mg	Trimethoprim with sulphamethoxazole [Co-trimoxazole]	Tab trimethoprim 160 mg and sulphamethoxazole 800 mg
Mefloquine hydrochloride	Tab 250 mg	Verapamil hydrochloride	Tab long-acting 120 mg
Methadone hydrochloride	Inj 10 mg per ml, 1 ml	Verapamil hydrochloride	Tab 40 mg
Methotrexate	Inj 100 mg per ml, 10 ml	Verapamil hydrochloride	Tab 80 mg
Orphenadrine Citrate	Tab 100 mg	Verapamil hydrochloride	Tab long-acting 240 mg
Paclitaxel	Inj 150 mg		

For products included in the 2014/15, 2015/16 and 2016/17 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.

If you have any queries regarding this notification, please contact PHARMAC on 0800 66 00 50.